The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine (Q83146475)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21212792%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21212792%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

ChEBI release 2020-05-28

1 reference

E Walsby

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21212792%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

M Lazenby

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21212792%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

C Pepper

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21212792%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

A K Burnett

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21212792%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

7 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21212792%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21212792%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21212792%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21212792%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

411-419

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21212792%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2010.290

19 January 2020

exact match

0 references

cites work

Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

FLT3 inhibition as a targeted therapy for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

Aurora kinases as targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

cdk-7 Is required for mRNA transcription and cell cycle progression in Caenorhabditis elegans embryos

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

Cyclin-dependent kinase pathways as targets for cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

CAK-Cyclin-dependent Activating Kinase: a key kinase in cell cycle control and a target for drugs?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

Cdk7 is essential for mitosis and for in vivo Cdk-activating kinase activity.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

The regulation and functions of cdk7.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and of the novel anti-apoptosis factors IAP (inhibitory of apoptosis proteins).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

Advances in the treatment of acute myeloid leukemia: from chromosomal aberrations to biologically targeted therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

New drugs in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

Cooperating gene mutations in acute myeloid leukemia: a review of the literature.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

Cell cycle molecular targets in novel anticancer drug discovery

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021

A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.290

7 January 2021